Can anti-IgE be an alternative treatment for severe non-allergic asthma?

References (1)

1. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302. 2.Sayama K, Diehn M, Matsuda K, Lunderius C, Tsai M, Tam SY, et al. Transcriptional response of human mast cells stimulated via the FcεRI and identification of mast cells as a source of IL- 11. BMC Immunol 2002; 3: 5. 3.Global Initiative of Asthma (GINA) guidelines. www.ginasthma.com 4.Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65. 5.van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011; 139: 190-3. 6.Sugino Y, Sanda R, Takagi Y, Kato M, Ohta A, Okumura J, et al. A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens]. Arerugi 2010; 59: 1572-9. Japanese. 7.Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in non-allergic individuals. Eur Respir J 2000; 16: 609-14. 8. Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi B, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and non-atopic asthma: evi- dence against “intrinsic” asthma being a distinct immunopat- hologic entity. Am J Respir Crit Care Med 1996; 154: 1497-504. 9. Kraft S, Kinet JP. New developments in FcεRI regulation, function and inhibition. Nature Rev Immunol 2007; 7: 365-78. 10. Bachert C, Gevaert P, Zhang N, van Zele T, Perez-Novo C. Role of staphylococcal superantigens in airway disease. Chem Immunol Allergy 2007; 93: 214-36. 11. Rondon C, Romero JJ, Lopez S, Antunez C, Martin-Casanez E, Torres MJ, et al. Local IgE production and positive nasal provocation test in patients with persistent non-allergic rhinitis. J Allergy Clin Immunol 2007; 119: 899-905. 12. Takhar P, Corrigan CJ, Smurthwaite L, O’Connor BJ, Durham SR, Lee TH, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and non-atopic patients with asthma. J Allergy Clin Immunol 2007; 119: 213-8. 13.Bhat KD, Calhoun WJ. Omalizumab in asthma: is the therapeutic window too small? Chest 2011; 139: 8-10.